Market Overview

JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference

Share:
JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference

The American Society of Clinical Oncology's 2018 annual meeting is scheduled to be held in Chicago, Illinois June 1-5.

In a Thursday note, JPMorgan evaluated the prospects for Dynavax Technologies Corporation (NASDAQ: DVAX) in the coming month, especially ahead of the ASCO presentations.

The Analyst

Analyst Anupam Rama upgraded Dynavax from Neutral to Overweight and increased the price target for the shares from $25 to $27.

The Thesis

Despite Dynavax' SD-101 showing encouraging early signals of efficacy in both melanoma and head and neck indications, the opportunity is grossly underappreciated at Dynavax's current valuation, Rama said in the note.

The launch inflection of Heplisav — the Berkley, California-based company's adult hepatitis B vaccine — is a 2019 event, the analyst said. The vaccine received the FDA's approval in November. 

"We view as a best-in-class Hepatitis B vaccine," Rama said. 

Previewing Dynavax' ASCO presentations, Rama said the company is likely to give a Phase 2 melanoma update, with an abstract, and data expected to be released May 16.

The reward-risk profile is attractive headed into the readout headed into the readout, Rama said, projecting 30-60-percent potential upside for shares as opposed to zero-to-10-percent downside at today's levels. 

Dynavax shares have lost about 20 percent since reaching year-to-date highs around the time of its presentations at the 2018 American Association for Cancer Research conference in mid-April.

" ... We believe the recent downside has created an interesting entry point ahead of ASCO, additional SD-101 readouts in 2018 and the Heplisav launch long-term." 

The Price Action

Dynavax shares were rallying 18.72 percent at the time of publication Thursday to $19.10. 

Related Links:

Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Latest Ratings for DVAX

DateFirmActionFromTo
Jul 2019UpgradesNeutralOverweight
Nov 2018MaintainsOutperformOutperform
May 2018UpgradesNeutralOverweight

View More Analyst Ratings for DVAX
View the Latest Analyst Ratings

Posted-In: Anupam Rama ASCOAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (DVAX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NCMIBenchmarkMaintains12.0
FWONAFBN SecuritiesDowngrades
BXCitiDowngrades52.0
TRVBank of AmericaDowngrades
PSTGCross ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

InvestCloud Develops Financial Solutions For The New Era Of Data Management

Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge